BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 26445087)

  • 1. Pediatric Targeted Therapy: Clinical Feasibility of Personalized Diagnostics in Children with Relapsed and Progressive Tumors.
    Selt F; Deiß A; Korshunov A; Capper D; Witt H; van Tilburg CM; Jones DT; Witt R; Sahm F; Reuss D; Kölsche C; Ecker J; Oehme I; Hielscher T; von Deimling A; Kulozik AE; Pfister SM; Witt O; Milde T
    Brain Pathol; 2016 Jul; 26(4):506-16. PubMed ID: 26445087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of actionable genetic alterations with targeted panel sequencing in children with relapsed or refractory solid tumors.
    Lee JW; Kim NKD; Lee SH; Cho HW; Ma Y; Ju HY; Yoo KH; Sung KW; Koo HH; Park WY
    PLoS One; 2019; 14(11):e0224227. PubMed ID: 31747416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular diagnostics enables detection of actionable targets: the Pediatric Targeted Therapy 2.0 registry.
    Ecker J; Selt F; Sturm D; Sill M; Korshunov A; Hirsch S; Capper D; Dikow N; Sutter C; Müller C; Sigaud R; Eggert A; Simon T; Niehues T; von Deimling A; Pajtler KW; van Tilburg CM; Jones DTW; Sahm F; Pfister SM; Witt O; Milde T
    Eur J Cancer; 2023 Feb; 180():71-84. PubMed ID: 36542877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study.
    Worst BC; van Tilburg CM; Balasubramanian GP; Fiesel P; Witt R; Freitag A; Boudalil M; Previti C; Wolf S; Schmidt S; Chotewutmontri S; Bewerunge-Hudler M; Schick M; Schlesner M; Hutter B; Taylor L; Borst T; Sutter C; Bartram CR; Milde T; Pfaff E; Kulozik AE; von Stackelberg A; Meisel R; Borkhardt A; Reinhardt D; Klusmann JH; Fleischhack G; Tippelt S; Dirksen U; Jürgens H; Kramm CM; von Bueren AO; Westermann F; Fischer M; Burkhardt B; Wößmann W; Nathrath M; Bielack SS; Frühwald MC; Fulda S; Klingebiel T; Koscielniak E; Schwab M; Tremmel R; Driever PH; Schulte JH; Brors B; von Deimling A; Lichter P; Eggert A; Capper D; Pfister SM; Jones DT; Witt O
    Eur J Cancer; 2016 Sep; 65():91-101. PubMed ID: 27479119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial.
    Harttrampf AC; Lacroix L; Deloger M; Deschamps F; Puget S; Auger N; Vielh P; Varlet P; Balogh Z; Abbou S; Allorant A; Valteau-Couanet D; Sarnacki S; Gamiche-Rolland L; Meurice G; Minard-Colin V; Grill J; Brugieres L; Dufour C; Gaspar N; Michiels S; Vassal G; Soria JC; Geoerger B
    Clin Cancer Res; 2017 Oct; 23(20):6101-6112. PubMed ID: 28733441
    [No Abstract]   [Full Text] [Related]  

  • 6. Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine.
    Tsimberidou AM; Hong DS; Wheler JJ; Falchook GS; Janku F; Naing A; Fu S; Piha-Paul S; Cartwright C; Broaddus RR; Nogueras Gonzalez GM; Hwu P; Kurzrock R
    J Hematol Oncol; 2019 Dec; 12(1):145. PubMed ID: 31888672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth.
    Mody RJ; Wu YM; Lonigro RJ; Cao X; Roychowdhury S; Vats P; Frank KM; Prensner JR; Asangani I; Palanisamy N; Dillman JR; Rabah RM; Kunju LP; Everett J; Raymond VM; Ning Y; Su F; Wang R; Stoffel EM; Innis JW; Roberts JS; Robertson PL; Yanik G; Chamdin A; Connelly JA; Choi S; Harris AC; Kitko C; Rao RJ; Levine JE; Castle VP; Hutchinson RJ; Talpaz M; Robinson DR; Chinnaiyan AM
    JAMA; 2015 Sep; 314(9):913-25. PubMed ID: 26325560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy.
    Kline CN; Joseph NM; Grenert JP; van Ziffle J; Talevich E; Onodera C; Aboian M; Cha S; Raleigh DR; Braunstein S; Torkildson J; Samuel D; Bloomer M; Campomanes AGA; Banerjee A; Butowski N; Raffel C; Tihan T; Bollen AW; Phillips JJ; Korn WM; Yeh I; Bastian BC; Gupta N; Mueller S; Perry A; Nicolaides T; Solomon DA
    Neuro Oncol; 2017 May; 19(5):699-709. PubMed ID: 28453743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preliminary experience with personalized and targeted therapy for pediatric brain tumors.
    Wolff JE; Brown RE; Buryanek J; Pfister S; Vats TS; Rytting ME
    Pediatr Blood Cancer; 2012 Jul; 59(1):27-33. PubMed ID: 22162424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive tumor profiling-guided therapy in rare or refractory solid cancer: A feasibility study in daily clinical practice.
    Ibrahim T; Ahmadie A; Rassy E; Karak FE; Hanna C; Farhat F; Kattan J; Ghosn M
    Bull Cancer; 2020 Apr; 107(4):410-416. PubMed ID: 32145962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of New Fusion Transcripts in a Cohort of Pediatric Solid Cancers at Relapse and Relevance for Personalized Medicine.
    Dupain C; Harttrampf AC; Boursin Y; Lebeurrier M; Rondof W; Robert-Siegwald G; Khoueiry P; Geoerger B; Massaad-Massade L
    Mol Ther; 2019 Jan; 27(1):200-218. PubMed ID: 30509566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Precision medicine in pediatric oncology.
    Forrest SJ; Geoerger B; Janeway KA
    Curr Opin Pediatr; 2018 Feb; 30(1):17-24. PubMed ID: 29189430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility of implementing molecular-guided therapy for the treatment of patients with relapsed or refractory neuroblastoma.
    Saulnier Sholler GL; Bond JP; Bergendahl G; Dutta A; Dragon J; Neville K; Ferguson W; Roberts W; Eslin D; Kraveka J; Kaplan J; Mitchell D; Parikh N; Merchant M; Ashikaga T; Hanna G; Lescault PJ; Siniard A; Corneveaux J; Huentelman M; Trent J
    Cancer Med; 2015 Jun; 4(6):871-86. PubMed ID: 25720842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A chemogenomic approach to identify personalized therapy for patients with relapse or refractory acute myeloid leukemia: results of a prospective feasibility study.
    Collignon A; Hospital MA; Montersino C; Courtier F; Charbonnier A; Saillard C; D'Incan E; Mohty B; Guille A; Adelaïde J; Carbuccia N; Garnier S; Mozziconacci MJ; Zemmour C; Pakradouni J; Restouin A; Castellano R; Chaffanet M; Birnbaum D; Collette Y; Vey N
    Blood Cancer J; 2020 Jun; 10(6):64. PubMed ID: 32488055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Precision Medicine in Pediatric Oncology.
    Vo KT; Parsons DW; Seibel NL
    Surg Oncol Clin N Am; 2020 Jan; 29(1):63-72. PubMed ID: 31757314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Italian Precision Medicine in Pediatric Oncology: Moving beyond Actionable Alterations.
    Pastorino F; Capasso M; Brignole C; Giglio S; Bensa V; Cantalupo S; Lasorsa VA; Tondo A; Mura R; Sementa AR; Garaventa A; Ponzoni M; Amoroso L
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrating Genomics Into Clinical Pediatric Oncology Using the Molecular Tumor Board at the Memorial Sloan Kettering Cancer Center.
    Ortiz MV; Kobos R; Walsh M; Slotkin EK; Roberts S; Berger MF; Hameed M; Solit D; Ladanyi M; Shukla N; Kentsis A
    Pediatr Blood Cancer; 2016 Aug; 63(8):1368-74. PubMed ID: 27082517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world performance analysis of a novel computational method in the precision oncology of pediatric tumors.
    Vodicska B; Déri J; Tihanyi D; Várkondi E; Kispéter E; Dóczi R; Lakatos D; Dirner A; Vidermann M; Filotás P; Szalkai-Dénes R; Szegedi I; Bartyik K; Gábor KM; Simon R; Hauser P; Péter G; Kiss C; Garami M; Peták I
    World J Pediatr; 2023 Oct; 19(10):992-1008. PubMed ID: 36914906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrative omics analyses broaden treatment targets in human cancer.
    Sengupta S; Sun SQ; Huang KL; Oh C; Bailey MH; Varghese R; Wyczalkowski MA; Ning J; Tripathi P; McMichael JF; Johnson KJ; Kandoth C; Welch J; Ma C; Wendl MC; Payne SH; Fenyö D; Townsend RR; Dipersio JF; Chen F; Ding L
    Genome Med; 2018 Jul; 10(1):60. PubMed ID: 30053901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial.
    Parsons DW; Janeway KA; Patton DR; Winter CL; Coffey B; Williams PM; Roy-Chowdhuri S; Tsongalis GJ; Routbort M; Ramirez NC; Saguilig L; Piao J; Alonzo TA; Berg SL; Fox E; Hawkins DS; Abrams JS; Mooney M; Takebe N; Tricoli JV; Seibel NL;
    J Clin Oncol; 2022 Jul; 40(20):2224-2234. PubMed ID: 35353553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.